Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organon Zemuron supply

Executive Summary

Organon's supply problems with the neuromuscular blocking agent Zemuron (rocuronium) have been resolved, according to the Center for Drug Evaluation & Research's drug shortages website. Zemuron 5 mL and 10 mL vials for injection have been in shortage since April 2004 due to manufacturing problems; the product is manufactured in the U.S. by Baxter. Supplies were expected to be normalized by fall 2004...

You may also be interested in...



Remote Site Visits Will Help US FDA Keep Reviews On Track As Pandemic Constraints Continue

Guidance discusses what are generically called virtual inspections, but which the agency terms “remote interactive evaluations.” As site inspections remain constrained by the pandemic, remote interactive evaluations “should help FDA operate within normal timeframes,” the document says.

Execs On The Move: Repro-Med Replaces Its CEO

At Repro-Med, James Beck has been replaced by Linda Tharby as CEO, and more.

Start-Up Spotlight: Pre Diagnostics Picks Up Momentum In Early Neurodegenerative Disease Detection

Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.

Topics

UsernamePublicRestriction

Register

PS045378

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel